KPV

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone — Lys-Pro-Val, residues 11–13, approximately 325 daltons. Fragment mapping of alpha-MSH localised the anti-inflammatory activity to this sequence; Hiltz and Lipton (1989) established it as the active anti-inflammatory sequence and demonstrated anti-pyretic effects.

The defining pharmacological feature is what it lacks. KPV does not bind melanocortin receptors, so it is free of the pigmentation, appetite, and sexual effects of the parent hormone and of MT-1 and MT-2. Its anti-inflammatory action runs through intracellular uptake via the PepT1 di/tripeptide transporter rather than receptor agonism, which is unusual among anti-inflammatory peptides.

Small size permits oral, subcutaneous, and topical routes. Subcutaneous injection is positioned for systemic anti-inflammatory and autoimmune-support use, oral for gut-targeted use, and topical for skin. Enteric activity remains the best-documented application, but the indication range spans dermatological, musculoskeletal, and gastrointestinal inflammation.

Antimicrobial activity against *S. aureus* and *C. albicans* is retained from alpha-MSH and is paired with rather than opposed to the anti-inflammatory profile — the same pairing that appears on the KLOW blend page where KPV is one of four components.

Evidence status: as of early 2026 all published work is preclinical — cell culture and animal models, principally DSS and TNBS mouse colitis. No human clinical trials and no human dose-finding studies exist by any route.

Subcutaneous administration after reconstitution with bacteriostatic water.

Primary mechanism is suppression of NF-kB activation, with downstream reduction in TNF-alpha, IL-1 beta, IL-6, and IL-8 production. KPV also inhibits MAP kinase inflammatory signalling, so both cascades are attenuated concurrently. Dalmasso et al. (2008) showed these effects at nanomolar concentrations.

The entry route is intracellular rather than receptor-mediated. KPV is transported into cells by PepT1, a di/tripeptide transporter expressed on intestinal epithelial cells and immune cells, and acts on NF-kB and MAP kinase signalling from within. The anti-inflammatory effect in Dalmasso et al. (2008) was PepT1-dependent, not melanocortin-receptor-dependent, and the 2016 follow-up confirmed dependence: KPV had no anti-tumour effect in PepT1 knockout mice.

PepT1 is upregulated in inflamed colon during inflammatory bowel disease, producing a self-targeting distribution — greater inflammation, greater transporter density, greater KPV uptake. This underpins the oral route for enteric indications; the subcutaneous route is positioned for systemic bioavailability where the target is outside the gut.

KPV is immunomodulatory rather than immunosuppressive. It does not produce the global suppression of corticosteroids, and it preserves and appears to enhance neutrophil pathogen killing. Cutuli et al. (2000) attributed the antimicrobial effect to increased cellular cAMP, with direct activity at concentrations as low as picomolar.

Anti-inflammatory: the core activity, effective in preclinical models of contact dermatitis, arthritis, colitis, and allergic asthma. Brzoska et al. (2008) described KPV as exerting "similar or even more pronounced anti-inflammatory activity" than full-length alpha-MSH, indicating modulation of fundamental pathways rather than disease-specific targeting.

Gastrointestinal: the most researched application. In DSS- and TNBS-induced colitis, oral KPV significantly reduced severity, decreased colonic pro-inflammatory cytokine expression, and protected barrier integrity; in one mouse study it rescued all animals from death during severe DSS colitis. Xiao et al. (2017) showed hyaluronic-acid-functionalised nanoparticles targeted inflamed tissue and outperformed free KPV on mucosal healing and inflammation. A 2025 systematic review in JGH Open ranked KPV among the most promising anti-inflammatory peptides for IBD while stressing the absence of human trials.

Dermatological: topical models of psoriasis, eczema, and wound healing show reduced inflammation and accelerated closure without corticosteroid-type skin thinning or immunosuppression; reduced scarring with improved collagen fibre organisation.

Repair: wound healing and accelerated recovery of damaged tissue; recovery from liver injury via increased hepatocyte replication; prolonged survival of grafted tissue.

Antimicrobial: direct activity against *S. aureus* and *C. albicans*, enhanced neutrophil pathogen killing, and stated antifungal activity.

Immune: stimulation of immune function in the direction of resolution rather than suppression.

Oncology: Dalmasso et al. (2016) found PepT1-mediated KPV prevented carcinogenesis in a murine colitis-associated cancer model. Mouse data only.

No human clinical data exist; expected timelines derive from preclinical models and anecdotal reports, and should be read accordingly.

In animal colitis models, measurable reductions in intestinal inflammation markers appeared within days of oral KPV, with mucosal healing and barrier restoration following over subsequent weeks.

Users report reduced bloating and improved digestion within 2 to 4 weeks for gut-directed use, with more significant improvement in inflammatory symptoms at 4 to 8 weeks of consistent dosing. Response is variable in more severe or suspected IBD presentations — meaningful improvement in some, minimal change in others.

For topical skin use, reduced erythema and irritation are reported within days, with more substantial change over 2 to 4 weeks.

KPV is not suited to acute inflammatory crises; it functions as a consistent daily intervention that lowers inflammatory burden progressively.

Tolerability is the most consistent report. Mild injection site irritation is the commonest subcutaneous complaint; erythema, swelling, pruritus, nausea, and fatigue are also listed. Preclinical studies report low toxicity and a favourable safety profile (Brzoska et al., 2008), but long-term human safety is unknown.

No published human dose-finding studies exist by any route. Practical protocols reflect clinical practice patterns.

Standard subcutaneous protocol. 200 to 400 mcg once daily for 4 to 8 weeks, positioned for systemic inflammation and autoimmune support. Refrigerate after reconstitution.

Reconstitution, 5 mg vial. 1 mL bacteriostatic water, giving 5 mg/mL — 250 mcg per 5 units, or 50 mcg per unit. 200 mcg = 4 units; 400 mcg = 8 units.

Titration variant. An alternative approach starts at 200 mcg once daily and increases in 100 mcg increments only as necessary to sustain benefit — reactive rather than scheduled — to a ceiling of 1 mg, a 5× range from the start dose. Under that scheme the cycle is 8 weeks followed by a 4–8 week washout, elsewhere stated as 4–6 weeks. At 50 mcg/unit the 100 mcg increment is exactly 2 units.

Alternative 10 mg presentation. Reconstitute with 2.5 mL (250 units) for 4 mg/mL — 40 mcg per unit. 200 mcg = 5 units; 400 mcg = 10 units; 1 mg = 25 units. The 100 mcg increment is 2.5 units, below syringe resolution, so it is rounded to 3 units (120 mcg); successive increments therefore run 20% larger than nominal, and by the fourth increment cumulative dose is 680 mcg rather than 600.

Timing. Administration time is free except for gut-repair use, where a fixed daily time is specified — consistent with an effect treated as exposure-consistency dependent rather than peak dependent. For enteric indications the oral route is favoured, 200 to 500 mcg once or twice daily for 4 to 8 weeks, extendable with monitoring, on the basis of PepT1 upregulation in inflamed colon. Topical use is 0.01 to 0.1% in cream base twice daily.

Monitoring. CRP and ESR where used for inflammatory conditions; symptom tracking for gut-related use.

The evidence base is entirely preclinical: cell culture and animal models, chiefly murine colitis. No human clinical trials and no human dose-finding studies exist by any route as of early 2026.

Dalmasso et al. (2008), Gastroenterology, is the landmark mechanism paper. Nanomolar KPV inhibited NF-kB and MAP kinase activation and reduced pro-inflammatory cytokine secretion (TNF-alpha, IL-1 beta, IL-6, IL-8 downstream). Uptake was PepT1-mediated, not melanocortin receptor-mediated. Oral KPV reduced colitis severity in both DSS and TNBS models with decreased colonic cytokine expression. In one DSS model KPV rescued all animals from death.

Xiao et al. (2017), Molecular Therapy: hyaluronic acid-functionalised nanoparticles loaded with KPV targeted inflamed colonic tissue, outperforming free KPV on mucosal healing and inflammation.

Dalmasso et al. (2016), Cellular and Molecular Gastroenterology and Hepatology: PepT1-mediated KPV prevented carcinogenesis in a colitis-associated cancer model; no anti-tumour effect in PepT1 knockout mice, confirming transporter dependence.

Hiltz and Lipton (1989), FASEB Journal: identified KPV as the active anti-inflammatory sequence of the alpha-MSH C-terminus and demonstrated anti-pyretic activity.

Brzoska et al. (2008), Endocrine Reviews: KPV exerts "similar or even more pronounced anti-inflammatory activity" than full-length alpha-MSH, effective in models of contact dermatitis, arthritis, colitis, and asthma; low toxicity noted.

Cutuli et al. (2000): direct antimicrobial activity against *S. aureus* and *C. albicans* at concentrations as low as picomolar, mediated via increased cellular cAMP; enhanced rather than reduced neutrophil pathogen killing.

A 2025 systematic review in JGH Open ranked KPV among the most promising anti-inflammatory peptides for IBD on preclinical grounds and emphasised the need for human trials.

Mechanistic note relevant to route choice: PepT1 is expressed in intestinal epithelium and immune cells and is upregulated in inflamed colon, producing a self-targeting effect for oral dosing. Systemic and dermatological indications are the rationale for the subcutaneous route.